Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-11-29

Clinical Trial Update: 24 Hour IOP Lowering Efficacy of AL-3789 [Phase 2]

View source ↗

Summary

Phase 2 study of AL-3789 in open-angle glaucoma reports 24-hour intraocular pressure lowering efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AL-3789

Snippet

Sponsor: Alcon Research | Conditions: Open-angle Glaucoma | Phase 2 | Status: COMPLETED